177 related articles for article (PubMed ID: 30186134)
1. Neurosarcoidosis following Immune Checkpoint Inhibition.
Dunn-Pirio AM; Shah S; Eckstein C
Case Rep Oncol; 2018; 11(2):521-526. PubMed ID: 30186134
[TBL] [Abstract][Full Text] [Related]
2. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
3. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
4. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
5. Management of immune-related adverse events resulting from immune checkpoint blockade.
Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
[TBL] [Abstract][Full Text] [Related]
6. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
McDonald MA; Sanghvi P; Bykowski J; Daniels GA
BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
[TBL] [Abstract][Full Text] [Related]
9. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.
Koelzer VH; Rothschild SI; Zihler D; Wicki A; Willi B; Willi N; Voegeli M; Cathomas G; Zippelius A; Mertz KD
J Immunother Cancer; 2016; 4():13. PubMed ID: 26981243
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
11. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
Almutairi AR; McBride A; Slack M; Erstad BL; Abraham I
Front Oncol; 2020; 10():91. PubMed ID: 32117745
[No Abstract] [Full Text] [Related]
12. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
13. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.
Villadolid J; Amin A
Transl Lung Cancer Res; 2015 Oct; 4(5):560-75. PubMed ID: 26629425
[TBL] [Abstract][Full Text] [Related]
15. Toxicity management of immunotherapy for patients with metastatic melanoma.
Linardou H; Gogas H
Ann Transl Med; 2016 Jul; 4(14):272. PubMed ID: 27563659
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
17. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.
Reuss JE; Kunk PR; Stowman AM; Gru AA; Slingluff CL; Gaughan EM
J Immunother Cancer; 2016; 4():94. PubMed ID: 28031822
[TBL] [Abstract][Full Text] [Related]
18. A Review of Immune-Mediated Adverse Events in Melanoma.
Kennedy LB; Salama AKS
Oncol Ther; 2019 Dec; 7(2):101-120. PubMed ID: 32699983
[TBL] [Abstract][Full Text] [Related]
19. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
Bello E; Cohen JV; Mino-Kenudson M; Dougan M
J Immunother Cancer; 2019 Feb; 7(1):41. PubMed ID: 30744698
[TBL] [Abstract][Full Text] [Related]
20. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
